ADMA Biologics Inc. Overview

ADMA Biologics, Inc., a biopharmaceutical company headquartered in Ramsey, United States, is making strides in the health care sector, particularly within the biotechnology industry. The company focuses on developing and commercializing human plasma and plasma-derived therapeutics aimed at supporting immunity-compromised patients.

Recent Financial Performance

As of June 9, 2025, ADMA Biologics Inc. reported a close price of $20.86 on the Nasdaq exchange. This figure is part of a broader financial context where the company’s stock has experienced significant fluctuations over the past year. The 52-week high was recorded at $25.67 on April 27, 2025, while the 52-week low was $10.21 on August 4, 2024. These figures highlight the volatility in the company’s stock performance over the past year.

Market Capitalization and Valuation

ADMA Biologics Inc. boasts a market capitalization of approximately $4.76 billion USD. The company’s price-to-earnings (P/E) ratio stands at 23.73, reflecting investor sentiment and expectations regarding its future earnings potential.

Industry Focus

Operating within the biotechnology sector, ADMA Biologics is dedicated to advancing therapies that cater to patients with compromised immune systems. The company’s commitment to innovation in plasma-derived therapeutics positions it as a key player in addressing critical health care needs.

Conclusion

ADMA Biologics Inc. continues to navigate the dynamic landscape of the biotechnology industry, focusing on its core mission of enhancing patient care through specialized therapeutics. With a solid market presence and a clear strategic direction, the company remains a significant entity in the health care sector.